comments relating to the proposed Consent Decree. Comments should be addressed to the Assistant Attorney General for the Environment and Natural Resources Division, Department of Justice, Washington, DC 20530, and should refer to *United States* v. *Payne and Dolan, Inc.*, DOJ Ref. #90–7–1–711.

The proposed Consent Decree may be examined at the office of the United States Attorney, United States Courthouse, 517 E. Wisconsin Avenue, Room 330, Milwaukee, Wisconsin 53202; the Region V Office of the Environmental Protection Agency, 77 West Jackson Blvd., Chicago, Illinois 60604; and at the Consent Decree Library, 1120 G Street, N.W., 4th Floor, Washington, DC 20005, (202) 624-0892. A copy of the proposed consent decree may be obtained in person or by mail from the Consent Decree Library. In requesting a copy please refer to the referenced case and enclose a check in the amount of \$7.25 (25 cents per page reproduction costs), payable to the Consent Decree Library.

### Bruce Gelber,

Acting Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 95–1825 Filed 1–24–95; 8:45 am] BILLING CODE 4410–01–M

## Notice of Lodging of Consent Decree Under Comprehensive Environmental Response, Compensation, and Liability Act

Notice is hereby given that on January 10, 1995, in *United States* v. *Seymour Recycling Corp.*, et al. (Civ. No. IP–80–4567–C), the United States lodged a proposed Consent Decree in the United States District Court for the Southern District of Indiana.

In Seymour Recycling, the United States sought recovery of response costs incurred by the United States at the Seymour Recycling Superfund site located in Seymour, Indiana, as well as performance of remedial action at the site. The proposed Decree would resolve the liability of Blatz Paint Company, one of the remaining defendants in this case, under Sections 106 and 107 of the Comprehensive Environmental Response, Compensation, and Liability Act ("CERCLA"), 42 U.S.C. 9606 & 9607, for recovery of response costs incurred by the United States at the Site and for future liability at the Site. Almost all other parties in Seymour Recycling have resolved their liability to the United States under prior cost recovery or remedial action settlements.

Under the terms of the proposed Consent Decree, Blatz Paint Company will pay the United States \$30,000 in return for covenants not to sue for past and future CERCLA liability at the Seymour Recycling Superfund Site.

The Department of Justice will receive, for a period of thirty (30) days from the date of this publication, comments relating to the proposed Consent Decree. Comments should be addressed to the Assistant attorney General, U.S. Department of Justice, Washington, D.C. 20530, and should refer to *United States* v. *Seymour Recycling Corp.*, et al., DOJ Ref. #62–26S–19.

The proposed Consent Decree may be examined at the office of the United States Attorney, Southern District of Indiana, 46 East Ohio Street (5th floor), Indianapolis, Indiana, and at the offices of the U.S. Environmental Protection Agency, Region 5, Office of Regional Counsel, 200 West Adams (29th Floor), Chicago, Illinois. Copies of the proposed Consent Decree may be obtained in person or by mail from the Consent Decree Library, 1120 G Street, N.W., 4th Floor, Washington, D.C. 20005, (202) 624–0892. In requesting a copy, please enclose a check in the amount of \$3.00 (25 cents per page reproduction costs), payable to the "Consent Decree Library.'

#### Bruce S. Gelber,

Acting Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 95–1823 Filed 1–24–95; 8:45 am] BILLING CODE 4410–01–M

## **Drug Enforcement Administration**

# Manufacturer of Controlled Substances; Notice of Registration

By Notice dated November 29, 1994, and published in the **Federal Register** on December 6, 1994, (59 FR 62750), Ansys, Inc., 2 Goodyear, Irvine, California 92718, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Phencyclidine (7471)1-Piperidinocyclohexane-	II
carbonitrile (8603)	II

No comments or objections have been received. Therefore, pursuant to Section 303 of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and Title 21, Code of Federal Regulations, Section 1301.54(e), the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the

application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: January 17, 1995.

#### Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95-1772 Filed 1-24-95; 8:45 am] BILLING CODE 4410-09-M

# Importation of Controlled Substances; Notice of Application

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Section 1311.42 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on November 21, 1994, Knight Seed Company, Inc., 151 W. 126th Street, Burnsville, Minnesota 55337, made application to the Drug Enforcement Administration to be registered as an importer of Marihuana (7360) a basic class of controlled substance in Schedule I.

This application is exclusively for the importation of marihuana seed which will be rendered non-viable and used as bird seed.

Any manufacturer holding, or applying for, registration as a bulk manufacturer of this basic class of controlled substance may file written comments on or objections to the application for a hearing on such application in accordance with 21 CFR 1301.54 in such form as prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than (30 days from publication).

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 (CFR 1311.42(b), (c), (d), (e), and (f). As noted in a previous notice at 40 FR 43745–46 (September 23, 1975), all applicants for

registration to import a basic class of any controlled substance in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42(a), (b), (c), (d), (e), and (f) are satisfied.

Dated: January 17, 1995.

### Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95-1774 Filed 1-24-95; 8:45 am]

BILLING CODE 4410-09-M

## Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.43(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on December 20, 1994, MD Pharmaceutical, Inc., 3501 West Garry Avenue, Santa Ana, California 92704, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Methylphenidate (1724)	
Diphenoxylate (9170)	

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the above application and may also file a written request for a hearing thereon in accordance with 21 CFR 1301.54 and in the form prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than February 24, 1995.

Dated: January 17, 1995.

# Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95-1773 Filed 1-24-95; 8:45 am]

BILLING CODE 4410-09-M

# Manufacturer of Controlled Substances; Notice of Registration

By Notice dated November 4, 1994, and published in the **Federal Register** on November 15, 1994, (59 FR 58857), Norac Company Inc., 405 S. Motor Avenue, Azusa, California 91702, made application to the Drug Enforcement Administration to be registered as a bulk manufacturer of Tetrahydrocannabinols (7370), a basic class of controlled substance listed in Schedule I.

No comments or objections have been received. Therefore, pursuant to Section 303 of the Comprenehsive Drug Abuse Prevention and Control Act of 1970 and Title 21, Code of Federal Regulations, § 1301.54(e), the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed above is granted.

Dated: January 17, 1995.

#### Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95–1770 Filed 1–24–95; 8:45 am] BILLING CODE 4410–09–M

## Manufacturer of Controlled Substances; Notice of Registration

By Notice dated November 29, 1994, and published in the **Federal Register** on December 6, 1994, (59 FR 62750), Upjohn Company, 7171 Portage Road, M.L. 7011–126–5, Kalamazoo, Michigan 49001, made application to the Drug Enforcement Administration to be registered as a bulk manufacturer of 2,5,-Dimethoxyamphetamine (7396), a basic class of controlled substance listed in Schedule I.

No comments or objections have been received. Therefore, pursuant to Section 303 of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and Title 21, Code of Federal Regulations, § 1301.54(e), the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed above is granted.

Dated: January 17, 1995.

## Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95–1771 Filed 1–24–95; 8:45 am] BILLING CODE 4410–09–M

### **DEPARTMENT OF LABOR**

## Pension and Welfare Benefits Administration

# Advisory Council on Employee Welfare and Pension Benefits Plan; Meeting

Pursuant to the authority contained in Section 512 of the Employee Retirement Income Security Act of 1974 (ERISA), 29 U.S.C. 1142, a public meeting of the Advisory Council on Employee Welfare and Pension Benefit Plans will be held on February 15, 1995, in Suite S–2508. U.S. Department of Labor Building, Third and Constitution Avenue NW., Washington, DC 20210.

The purpose of the meeting, which will begin at 9:30 a.m. is to consider the items listed below and to invite public comment on any aspect of the administration of ERISA.

- I. Welcome and Introduction of New Council Members
- II. Assistant Secretary's Report A. PWBA Priorities for 1995
  - B. Report to Congress
  - C. Miscellaneous Issues
- D. Announcement of Council Chairperson and Vice Chairperson
- III. Introduction of PWBA Senior Staff and Orientation of New Members
- IV. Report of Advisory Council Working Groups (1993/1994 Term)
- V. Determination of Council Working Group/s for 1995
- VI. Procedure for Establishing Council and Working Group Meeting Dates VII. Statements From the General Public VIII. Adjourn

Members of the public are encouraged to file a written statement pertaining to any topic concerning ERISA by submitting twenty (20) copies on or before February 10, 1995 to William E. Morrow, Executive Secretary, ERISA Advisory Council, U.S. Department Labor, Suite N-5677, 200 Constitution Avenue, NW., Washington, DC 20210. Individuals or representatives of organizations wishing to address the Advisory Council should forward their request to the Executive Secretary or telephone (202) 219-8753. Oral presentations will be limited to ten minutes, but an extended statement may be submitted for the record.

Organizations or individuals may also submit statements for the record without testifying. Twenty (20) copies of such statements should be sent to the Executive Secretary of the Advisory Council at the above address. Papers will be accepted and included in the record of the meeting if received on or before February 10, 1995.